{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:37:56Z","timestamp":1791959876830,"version":"4.3.4"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Until relatively recently, a diagnosis of probable Alzheimer\u2019s disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold standard for disease confirmation. This is in sharp contrast to other areas of medicine, where fluid biomarkers, such as troponin levels in myocardial infarction, form an integral part of the diagnostic and treatment criteria. There is a pressing need for such quantifiable and easily accessible tools in neurodegenerative diseases.<\/jats:p><jats:p>In this paper, based on lectures given at the 2019 Biomarkers in Neurodegenerative Diseases Course, we provide an overview of a range of cerebrospinal fluid (CSF) and blood biomarkers in neurodegenerative disorders, including the \u2018core\u2019 AD biomarkers amyloid \u03b2 (A\u03b2) and tau, as well as other disease-specific and general markers of neuroaxonal injury. We then highlight the main challenges in the field, and how those could be overcome with the aid of new methodological advances, such as assay automation, mass spectrometry and ultrasensitive immunoassays.<\/jats:p><jats:p>As we hopefully move towards an era of disease-modifying treatments, reliable biomarkers will be essential to increase diagnostic accuracy, allow for earlier diagnosis, better participant selection and disease activity and treatment effect monitoring.<\/jats:p>","DOI":"10.1186\/s13195-020-00586-6","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T19:02:41Z","timestamp":1582916561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course\u2014a joint PhD student course at University College London and University of Gothenburg"],"prefix":"10.1186","volume":"12","author":[{"given":"Pawel","family":"Obrocki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Khatun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Senkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hanrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Capraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Andreasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Portelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross W.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"issue":"4","key":"586_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29653606.","journal-title":"Alzheimers Dement"},{"key":"586_CR2","volume-title":"Dementia: assessment, management and support for people living with dementia and their carers (NICE guideline [NG97])","author":"Excellence NI for H and C","year":"2018","unstructured":"Excellence NI for H and C. Dementia: assessment, management and support for people living with dementia and their carers (NICE guideline [NG97]). 2018."},{"issue":"6","key":"586_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"key":"586_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/B978-0-12-804279-3.00006-X","volume":"146","author":"H Zetterberg","year":"2017","unstructured":"Zetterberg H, Rohrer JD, Schott JM. Cerebrospinal fluid in the dementias. Handb Clin Neurol. 2017;146:85\u201397.","journal-title":"Handb Clin Neurol"},{"key":"586_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jneumeth.2018.10.025","volume":"319","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H. Blood-based biomarkers for Alzheimer\u2019s disease-An update. J Neurosci Methods. 2019;319:2\u20136.","journal-title":"J Neurosci Methods"},{"issue":"7","key":"586_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"1","key":"586_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","volume":"69","author":"P Buchhave","year":"2012","unstructured":"Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98\u2013106.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"586_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60(4):652\u20136.","journal-title":"Neurology."},{"issue":"10","key":"586_CR9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","volume":"71","author":"S Palmqvist","year":"2014","unstructured":"Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71(10):1282\u20139.","journal-title":"JAMA Neurol"},{"issue":"3","key":"586_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF Abeta42\/Abeta40 and Abeta42\/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3(3):154\u201365.","journal-title":"Ann Clin Transl Neurol."},{"issue":"1","key":"586_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(1):34.","journal-title":"Alzheimers Res Ther"},{"key":"586_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fnagi.2017.00210","volume":"9","author":"C Lauridsen","year":"2017","unstructured":"Lauridsen C, Sando SB, Moller I, Berge G, Pomary PK, Grontvedt GR, et al. Cerebrospinal fluid Abeta43 is reduced in early-onset compared to late-onset Alzheimer\u2019s disease, but has similar diagnostic accuracy to Abeta42. Front Aging Neurosci. 2017;9:210.","journal-title":"Front Aging Neurosci"},{"key":"586_CR13","doi-asserted-by":"publisher","first-page":"10918","DOI":"10.1038\/ncomms10918","volume":"7","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Insel PS, Palmqvist S, Stomrud E, van Westen D, Minthon L, et al. Increased amyloidogenic APP processing in APOE varepsilon4-negative individuals with cerebral beta-amyloidosis. Nat Commun. 2016;7:10918.","journal-title":"Nat Commun"},{"issue":"7","key":"586_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2217\/bmm-2017-0433","volume":"12","author":"NJ Ashton","year":"2018","unstructured":"Ashton NJ, Scholl M, Heurling K, Gkanatsiou E, Portelius E, Hoglund K, et al. Update on biomarkers for amyloid pathology in Alzheimer\u2019s disease. Biomark Med. 2018;12(7):799\u2013812.","journal-title":"Biomark Med"},{"issue":"5","key":"586_CR15","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, et al. Plasma amyloid as Prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648\u201358.","journal-title":"Ann Neurol"},{"key":"586_CR16","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6:26801.","journal-title":"Sci Rep"},{"issue":"4","key":"586_CR17","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3233\/JAD-170784","volume":"62","author":"CE Teunissen","year":"2018","unstructured":"Teunissen CE, Chiu M-J, Yang C-C, Yang S-Y, Scheltens P, Zetterberg H, et al. Plasma amyloid-beta (Abeta42) correlates with cerebrospinal fluid Abeta42 in Alzheimer\u2019s disease. J Alzheimers Dis. 2018;62(4):1857\u201363.","journal-title":"J Alzheimers Dis"},{"key":"586_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fnagi.2018.00175","volume":"10","author":"L-Y Fan","year":"2018","unstructured":"Fan L-Y, Tzen K-Y, Chen Y-F, Chen T-F, Lai Y-M, Yen R-F, et al. The relation between Brain amyloid deposition, cortical atrophy, and plasma biomarkers in amnesic mild cognitive impairment and Alzheimer\u2019s disease. Front Aging Neurosci. 2018;10:175.","journal-title":"Front Aging Neurosci"},{"issue":"25","key":"586_CR19","doi-asserted-by":"publisher","first-page":"11993","DOI":"10.1073\/pnas.91.25.11993","volume":"91","author":"M Citron","year":"1994","unstructured":"Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci U S A. 1994;91(25):11993\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"586_CR20","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.0b013e3181dd4dd8","volume":"74","author":"AK Wallin","year":"2010","unstructured":"Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010;74(19):1531\u20137.","journal-title":"Neurology."},{"issue":"1","key":"586_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110\u20139.","journal-title":"Ann Neurol"},{"issue":"Pt 11","key":"586_CR22","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awl269","volume":"129","author":"K Buerger","year":"2006","unstructured":"Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease. Brain. 2006;129(Pt 11):3035\u201341.","journal-title":"Brain."},{"issue":"9","key":"586_CR23","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.15252\/emmm.201707809","volume":"9","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Scholl M, Strandberg O, Smith R, Palmqvist S, Insel PS, et al. (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer\u2019s disease. EMBO Mol Med. 2017;9(9):1212\u201323.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"586_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","volume":"137","author":"C Cicognola","year":"2019","unstructured":"Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease. Acta Neuropathol. 2019;137(2):279\u201396.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"586_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/brain\/awz346","volume":"143","author":"Kaj Blennow","year":"2019","unstructured":"Blennow K, Chen C, Cicognola C, Wildsmith KR, Manser PT, Bohorquez SMS, et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain. 2020;143(2):650\u201360.","journal-title":"Brain"},{"key":"586_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fnagi.2019.00121","volume":"11","author":"NR Barthelemy","year":"2019","unstructured":"Barthelemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer\u2019s Disease. Front Aging Neurosci. 2019;11:121.","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"586_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/nan.12378","volume":"43","author":"H Zetterberg","year":"2017","unstructured":"Zetterberg H. Review: tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol. 2017;43(3):194\u20139.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"586_CR28","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1212\/WNL.59.4.627","volume":"59","author":"K Buerger","year":"2002","unstructured":"Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59(4):627\u20139.","journal-title":"Neurology."},{"issue":"1","key":"586_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61(1):95\u2013102.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"586_CR30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato C, Barthelemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, et al. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 2018;97(6):1284\u201398. e7.","journal-title":"Neuron"},{"issue":"6","key":"586_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","volume":"136","author":"JL Molinuevo","year":"2018","unstructured":"Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, et al. Current state of Alzheimer\u2019s fluid biomarkers. Acta Neuropathol. 2018;136(6):821\u201353.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"586_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","volume":"5","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, et al. Plasma tau levels in Alzheimer\u2019s disease. Alzheimers Res Ther. 2013;5(2):9.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"586_CR33","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989\u201397.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"586_CR34","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. 2019;11(12):e11170.","journal-title":"EMBO Mol Med."},{"issue":"4","key":"586_CR35","doi-asserted-by":"publisher","first-page":"a018309","DOI":"10.1101\/cshperspect.a018309","volume":"9","author":"Aidong Yuan","year":"2017","unstructured":"Yuan A, Rao M V, Veeranna, Nixon RA. Neurofilaments and Neurofilament Proteins in Health and Disease. Cold Spring Harb Perspect Biol. 2017;9(4):a018309.","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"9","key":"586_CR36","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/archneur.63.9.1277","volume":"63","author":"H Zetterberg","year":"2006","unstructured":"Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, et al. Neurochemical aftermath of amateur boxing. Arch Neurol. 2006;63(9):1277\u201380.","journal-title":"Arch Neurol"},{"issue":"20","key":"586_CR37","doi-asserted-by":"publisher","first-page":"e1780","DOI":"10.1212\/WNL.0000000000005518","volume":"90","author":"P Shahim","year":"2018","unstructured":"Shahim P, Tegner Y, Marklund N, Blennow K, Zetterberg H. Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology. 2018;90(20):e1780\u20138.","journal-title":"Neurology."},{"key":"586_CR38","doi-asserted-by":"crossref","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cermeno JC, et al. Diagnostic value of cerebrospinal fluid Neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76(9):1035\u201348.","DOI":"10.1001\/jamaneurol.2019.1534"},{"issue":"6","key":"586_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857\u201370.","journal-title":"Ann Neurol"},{"issue":"9","key":"586_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075091","volume":"8","author":"J Gaiottino","year":"2013","unstructured":"Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8(9):e75091.","journal-title":"PLoS One"},{"issue":"1","key":"586_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-019-0472-5","volume":"11","author":"PSJ Weston","year":"2019","unstructured":"Weston PSJ, Poole T, O\u2019Connor A, Heslegrave A, Ryan NS, Liang Y, et al. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(1):19.","journal-title":"Alzheimers Res Ther"},{"issue":"21","key":"586_CR42","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","volume":"89","author":"PSJ Weston","year":"2017","unstructured":"Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology. 2017;89(21):2167\u201375.","journal-title":"Neurology."},{"issue":"2","key":"586_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383.","journal-title":"Nat Med"},{"issue":"5","key":"586_CR44","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of Plasma Neurofilament Light with Neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557\u201366.","journal-title":"JAMA Neurol."},{"issue":"1","key":"586_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-018-0649-3","volume":"7","author":"NJ Ashton","year":"2019","unstructured":"Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobagyi T, Hoglund K, et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun. 2019;7(1):5.","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"586_CR46","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"Niklas Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019;76(7):791\u20139.","journal-title":"JAMA Neurology"},{"issue":"3","key":"586_CR47","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","volume":"76","author":"B Olsson","year":"2019","unstructured":"Olsson B, Portelius E, Cullen NC, Sandelius A, Zetterberg H, Andreasson U, et al. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels with Cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76(3):318\u201325.","journal-title":"JAMA Neurol."},{"issue":"13","key":"586_CR48","doi-asserted-by":"publisher","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","volume":"92","author":"TM Marques","year":"2019","unstructured":"Marques TM, van Rumund A, Oeckl P, Kuiperij HB, Esselink RAJ, Bloem BR, et al. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology. 2019;92(13):e1479\u201386.","journal-title":"Neurology."},{"issue":"10","key":"586_CR49","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88(10):930\u20137.","journal-title":"Neurology."},{"issue":"458","key":"586_CR50","doi-asserted-by":"publisher","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","volume":"10","author":"Lauren M. Byrne","year":"2018","unstructured":"Byrne LM, Rodrigues FB, Johnson EB, Wijeratne PA, De Vita E, Alexander DC, et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci Transl Med. 2018;10(458):eaat7108.","journal-title":"Science Translational Medicine"},{"issue":"8","key":"586_CR51","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"586_CR52","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1136\/jnnp-2018-320155","volume":"90","author":"K Blennow","year":"2019","unstructured":"Blennow K, Diaz-Lucena D, Zetterberg H, Villar-Pique A, Karch A, Vidal E, et al. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD. J Neurol Neurosurg Psychiatry. 2019;90(8):846\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"586_CR53","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/sj.mp.4001220","volume":"8","author":"M Riemenschneider","year":"2003","unstructured":"Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, et al. Phospho-tau\/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt\u2013Jakob disease from other dementias. Mol Psychiatry. 2003;8(3):343\u20137. Available from: https:\/\/doi.org\/10.1038\/sj.mp.4001220.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"586_CR54","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","volume":"213","author":"B Mollenhauer","year":"2008","unstructured":"Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213(2):315\u201325.","journal-title":"Exp Neurol"},{"issue":"12","key":"586_CR55","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1177\/1352458513482374","volume":"19","author":"J Kuhle","year":"2013","unstructured":"Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler. 2013;19(12):1597\u2013603.","journal-title":"Mult Scler"},{"issue":"22","key":"586_CR56","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","volume":"89","author":"L Novakova","year":"2017","unstructured":"Novakova L, Zetterberg H, Sundstrom P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230\u20137.","journal-title":"Neurology."},{"issue":"2","key":"586_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1212\/WNL.0000000000002832","volume":"87","author":"P de Flon","year":"2016","unstructured":"de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016;87(2):141\u20137.","journal-title":"Neurology."},{"issue":"10","key":"586_CR58","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577\u201389.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"586_CR59","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"Bob Olsson","year":"2019","unstructured":"Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark A-K, et al. NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol. 2019;266(9):2129\u201336.","journal-title":"Journal of Neurology"},{"issue":"5","key":"586_CR60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457\u201364.","journal-title":"Ann Neurol"},{"issue":"8","key":"586_CR61","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/iub.357","volume":"62","author":"FJ Diez-Guerra","year":"2010","unstructured":"Diez-Guerra FJ. Neurogranin, a link between calcium\/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life. 2010;62(8):597\u2013606.","journal-title":"IUBMB Life"},{"issue":"Pt 11","key":"586_CR62","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillback T, Tornqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain. 2015;138(Pt 11):3373\u201385.","journal-title":"Brain."},{"issue":"9","key":"586_CR63","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"Wellington H, Paterson RW, Portelius E, Tornqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829\u201335.","journal-title":"Neurology."},{"issue":"3","key":"586_CR64","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","volume":"136","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, Hoglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136(3):363\u201376.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"586_CR65","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00401-018-1910-3","volume":"137","author":"H Kvartsberg","year":"2019","unstructured":"Kvartsberg H, Lashley T, Murray CE, Brinkmalm G, Cullen NC, H\u00f6glund K, et al. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer\u2019s disease. Acta Neuropathol. 2019;137(1):89\u2013102.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"586_CR66","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","volume":"7","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, et al. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls. Alzheimers Res Ther. 2015;7(1):40.","journal-title":"Alzheimers Res Ther"},{"key":"586_CR67","first-page":"63","volume":"3","author":"CN Winston","year":"2016","unstructured":"Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, et al. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimer\u2019s Dement (Amsterdam, Netherlands). 2016;3:63\u201372.","journal-title":"Alzheimer\u2019s Dement (Amsterdam, Netherlands)"},{"key":"586_CR68","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Prim. 2017;3:17013.","journal-title":"Nat Rev Dis Prim"},{"issue":"Suppl 1","key":"586_CR69","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/S1353-8020(13)70017-8","volume":"20","author":"H McCann","year":"2014","unstructured":"McCann H, Stevens CH, Cartwright H, Halliday GM. alpha-Synucleinopathy phenotypes. Parkinsonism Relat Disord. 2014;20(Suppl 1):S62\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"586_CR70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ane.12247","volume":"130","author":"N Malek","year":"2014","unstructured":"Malek N, Swallow D, Grosset KA, Anichtchik O, Spillantini M, Grosset DG. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson\u2019s disease - a systematic review. Acta Neurol Scand. 2014;130(2):59\u201372.","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"586_CR71","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/mds.27110","volume":"32","author":"P Eusebi","year":"2017","unstructured":"Eusebi P, Giannandrea D, Biscetti L, Abraha I, Chiasserini D, Orso M, et al. Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2017;32(10):1389\u2013400.","journal-title":"Mov Disord"},{"issue":"Pt 3","key":"586_CR72","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/brain\/awq008","volume":"133","author":"Z Hong","year":"2010","unstructured":"Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson\u2019s disease. Brain. 2010;133(Pt 3):713\u201326.","journal-title":"Brain."},{"issue":"1","key":"586_CR73","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","volume":"84","author":"S Hall","year":"2015","unstructured":"Hall S, Surova Y, Ohrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology. 2015;84(1):57\u201363.","journal-title":"Neurology."},{"issue":"10","key":"586_CR74","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1074\/mcp.M116.059915","volume":"15","author":"P Oeckl","year":"2016","unstructured":"Oeckl P, Metzger F, Nagl M, von Arnim CAF, Halbgebauer S, Steinacker P, et al. Alpha-, Beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer\u2019s and Creutzfeldt-Jakob disease but no alteration in Synucleinopathies. Mol Cell Proteomics. 2016;15(10):3126\u201338.","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"586_CR75","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman BR, Orr\u00f9 CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B, et al. Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC. Acta Neuropathol Commun. 2018;6(1):7.","journal-title":"Acta Neuropathol Commun."},{"issue":"10","key":"586_CR76","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812\u20138.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"586_CR77","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C, et al. Development of a biochemical diagnosis of Parkinson disease by detection of alpha-Synuclein Misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 2017;74(2):163\u201372.","journal-title":"JAMA Neurol."},{"issue":"6","key":"586_CR78","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol. 2019;18(6):573\u201386.","journal-title":"Lancet Neurol"},{"issue":"2","key":"586_CR79","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000112832","volume":"5","author":"R Barbour","year":"2008","unstructured":"Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 2008;5(2):55\u20139.","journal-title":"Neurodegener Dis"},{"issue":"1","key":"586_CR80","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejn.13056","volume":"43","author":"SM Williams","year":"2016","unstructured":"Williams SM, Schulz P, Sierks MR. Oligomeric alpha-synuclein and beta-amyloid variants as potential biomarkers for Parkinson\u2019s and Alzheimer\u2019s diseases. Eur J Neurosci. 2016;43(1):3\u201316.","journal-title":"Eur J Neurosci"},{"key":"586_CR81","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mcn.2018.10.003","volume":"97","author":"P Steinacker","year":"2019","unstructured":"Steinacker P, Barschke P, Otto M. Biomarkers for diseases with TDP-43 pathology. Mol Cell Neurosci. 2019;97:43\u201359.","journal-title":"Mol Cell Neurosci"},{"issue":"5\u20136","key":"586_CR82","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/21678421.2014.905606","volume":"15","author":"E Feneberg","year":"2014","unstructured":"Feneberg E, Steinacker P, Lehnert S, Schneider A, Walther P, Thal DR, et al. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5\u20136):351\u20136.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"11","key":"586_CR83","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/archneur.65.11.1481","volume":"65","author":"P Steinacker","year":"2008","unstructured":"Steinacker P, Hendrich C, Sperfeld AD, Jesse S, von Arnim CAF, Lehnert S, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol. 2008;65(11):1481\u20137.","journal-title":"Arch Neurol"},{"issue":"2","key":"586_CR84","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00401-008-0389-8","volume":"116","author":"P Foulds","year":"2008","unstructured":"Foulds P, McAuley E, Gibbons L, Davidson Y, Pickering-Brown SM, Neary D, et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Acta Neuropathol. 2008;116(2):141\u20136.","journal-title":"Acta Neuropathol"},{"key":"586_CR85","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","volume":"11","author":"A Heslegrave","year":"2016","unstructured":"Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer\u2019s disease. Mol Neurodegener. 2016;11:3.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"586_CR86","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-018-0353-3","volume":"10","author":"F Brosseron","year":"2018","unstructured":"Brosseron F, Traschutz A, Widmann CN, Kummer MP, Tacik P, Santarelli F, et al. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10(1):25.","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"586_CR87","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry. 2010;68(10):903\u201312.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"586_CR88","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12974-017-0893-7","volume":"14","author":"M Querol-Vilaseca","year":"2017","unstructured":"Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, San Martin-Paniello C, Clarimon J, Belbin O, et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer\u2019s disease and other tauopathies. J Neuroinflammation. 2017;14(1):118.","journal-title":"J Neuroinflammation"},{"issue":"Pt 5","key":"586_CR89","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/awn034","volume":"131","author":"M Ewers","year":"2008","unstructured":"Ewers M, Zhong Z, Burger K, Wallin A, Blennow K, Teipel SJ, et al. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer\u2019s disease. Brain. 2008;131(Pt 5):1252\u20138.","journal-title":"Brain."},{"issue":"8","key":"586_CR90","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1001\/archneur.65.8.1102","volume":"65","author":"H Zetterberg","year":"2008","unstructured":"Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008;65(8):1102\u20137.","journal-title":"Arch Neurol"},{"issue":"5","key":"586_CR91","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopsych.2017.02.007","volume":"83","author":"Y Shen","year":"2018","unstructured":"Shen Y, Wang H, Sun Q, Yao H, Keegan AP, Mullan M, et al. Increased plasma Beta-Secretase 1 may predict conversion to Alzheimer\u2019s disease dementia in individuals with mild cognitive impairment. Biol Psychiatry. 2018;83(5):447\u201355.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"586_CR92","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","volume":"8","author":"A \u00d6hrfelt","year":"2016","unstructured":"\u00d6hrfelt A, Brinkmalm A, Dumurgier J, Brinkmalm G, Hansson O, Zetterberg H, et al. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8(1):41. Available from: https:\/\/doi.org\/10.1186\/s13195-016-0208-8.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"586_CR93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","volume":"15","author":"A Sandelius","year":"2019","unstructured":"Sandelius A, Portelius E, Kallen A, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology. Alzheimers Dement. 2019;15(1):55\u201364.","journal-title":"Alzheimers Dement"},{"key":"586_CR94","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm A, Brinkmalm G, Honer WG, Frolich L, Hausner L, Minthon L, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:53.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"586_CR95","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jalz.2015.08.003","volume":"12","author":"FH Duits","year":"2016","unstructured":"Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lleo A, Hausner L, et al. Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement. 2016;12(2):154\u201363.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"586_CR96","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13041-019-0448-1","volume":"12","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer\u2019s disease. Mol Brain. 2019;12(1):26. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30922367.","journal-title":"Mol Brain"},{"issue":"1","key":"586_CR97","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-2012-120361","volume":"31","author":"A Perret-Liaudet","year":"2012","unstructured":"Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Risk of Alzheimer\u2019s disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis. 2012;31(1):13\u201320.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"586_CR98","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","volume":"9","author":"N Mattsson","year":"2013","unstructured":"Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer\u2019s association quality control program. Alzheimers Dement. 2013;9(3):251\u201361.","journal-title":"Alzheimers Dement"},{"key":"586_CR99","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cca.2015.05.024","volume":"449","author":"A Fourier","year":"2015","unstructured":"Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A. Pre-analytical and analytical factors influencing Alzheimer\u2019s disease cerebrospinal fluid biomarker variability. Clin Chim Acta. 2015;449:9\u201315.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"586_CR100","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","volume":"12","author":"T Bittner","year":"2016","unstructured":"Bittner T, Zetterberg H, Teunissen CE, Ostlund REJ, Militello M, Andreasson U, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12(5):517\u201326.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"586_CR101","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643\u201363.","journal-title":"J Intern Med"},{"issue":"7","key":"586_CR102","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1515\/cclm-2015-0733","volume":"54","author":"M Bjerke","year":"2016","unstructured":"Bjerke M, Andreasson U, Kuhlmann J, Portelius E, Pannee J, Lewczuk P, et al. Assessing the commutability of reference material formats for the harmonization of amyloid-beta measurements. Clin Chem Lab Med. 2016;54(7):1177\u201391.","journal-title":"Clin Chem Lab Med"},{"issue":"11","key":"586_CR103","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470\u201381.","journal-title":"Alzheimers Dement"},{"key":"586_CR104","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2016.05.014","volume":"467","author":"J Kuhlmann","year":"2017","unstructured":"Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, et al. CSF Abeta1-42 - an excellent but complicated Alzheimer\u2019s biomarker - a route to standardisation. Clin Chim Acta. 2017;467:27\u201333.","journal-title":"Clin Chim Acta"},{"key":"586_CR105","first-page":"98","volume":"3","author":"U Andreasson","year":"2016","unstructured":"Andreasson U, Blennow K, Zetterberg H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimer\u2019s Dement (Amsterdam, Netherlands). 2016;3:98\u2013102.","journal-title":"Alzheimer\u2019s Dement (Amsterdam, Netherlands)"},{"issue":"4","key":"586_CR106","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/jnc.14635","volume":"151","author":"Eugene M. Cilento","year":"2019","unstructured":"Cilento EM, Jin L, Stewart T, Shi M, Sheng L, Zhang J. Mass spectrometry: a platform for biomarker discovery and validation for Alzheimer\u2019s and Parkinson\u2019s diseases. J Neurochem. 2019;151(4):397\u2013416.","journal-title":"Journal of Neurochemistry"},{"issue":"2","key":"586_CR107","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/JAD-132489","volume":"41","author":"M Korecka","year":"2014","unstructured":"Korecka M, Waligorska T, Figurski M, Toledo JB, Arnold SE, Grossman M, et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis. 2014;41(2):441\u201351.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"586_CR108","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1373\/clinchem.2013.220392","volume":"60","author":"A Leinenbach","year":"2014","unstructured":"Leinenbach A, Pannee J, Dulffer T, Huber A, Bittner T, Andreasson U, et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin Chem. 2014;60(7):987\u201394.","journal-title":"Clin Chem"},{"issue":"9","key":"586_CR109","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2183\/pjab.90.353","volume":"90","author":"N Kaneko","year":"2014","unstructured":"Kaneko N, Nakamura A, Washimi Y, Kato T, Sakurai T, Arahata Y, et al. Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(9):353\u201364.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"7691","key":"586_CR110","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature."},{"issue":"8","key":"586_CR111","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139.","journal-title":"Alzheimers Dement"},{"key":"586_CR112","doi-asserted-by":"crossref","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359.","DOI":"10.1212\/WNL.0000000000008081"},{"issue":"4","key":"586_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9(4):e95192.","journal-title":"PLoS One"},{"issue":"1","key":"586_CR114","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer\u2019s disease. Acta Neuropathol Commun. 2019;7(1):169.","journal-title":"Acta Neuropathol Commun."},{"issue":"7","key":"586_CR115","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/jnnp-2018-320151","volume":"90","author":"E Jabbari","year":"2019","unstructured":"Jabbari E, Woodside J, Guo T, Magdalinou NK, Chelban V, Athauda D, et al. Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2019;90(7):768\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"586_CR116","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrm.2016.25","volume":"17","author":"CH Johnson","year":"2016","unstructured":"Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17(7):451\u20139.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"586_CR117","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrm3314","volume":"13","author":"GJ Patti","year":"2012","unstructured":"Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13(4):263\u20139.","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"2","key":"586_CR118","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s11306-012-0482-9","volume":"9","author":"J Xia","year":"2013","unstructured":"Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013;9(2):280\u201399.","journal-title":"Metabolomics."},{"key":"586_CR119","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fneur.2015.00237","volume":"6","author":"MS Fiandaca","year":"2015","unstructured":"Fiandaca MS, Zhong X, Cheema AK, Orquiza MH, Chidambaram S, Tan MT, et al. Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer\u2019s disease. Front Neurol. 2015;6:237.","journal-title":"Front Neurol"},{"issue":"7","key":"586_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021643","volume":"6","author":"X Han","year":"2011","unstructured":"Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, et al. Metabolomics in early Alzheimer\u2019s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One. 2011;6(7):e21643.","journal-title":"PLoS One"},{"issue":"3","key":"586_CR121","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jalz.2010.06.001","volume":"7","author":"R Kaddurah-Daouk","year":"2011","unstructured":"Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, Burke JR, et al. Metabolomic changes in autopsy-confirmed Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):309\u201317.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"586_CR122","first-page":"295","volume":"1","author":"K Klavins","year":"2015","unstructured":"Klavins K, Koal T, Dallmann G, Marksteiner J, Kemmler G, Humpel C. The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer\u2019s disease and mild cognitive impairment. Alzheimer\u2019s Dement (Amsterdam, Netherlands). 2015;1(3):295\u2013302.","journal-title":"Alzheimer\u2019s Dement (Amsterdam, Netherlands)"},{"issue":"4","key":"586_CR123","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3233\/JAD-142319","volume":"44","author":"T Koal","year":"2015","unstructured":"Koal T, Klavins K, Seppi D, Kemmler G, Humpel C. Sphingomyelin SM(d18:1\/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-beta42, tau, and phospho-tau-181 levels. J Alzheimers Dis. 2015;44(4):1193\u2013201.","journal-title":"J Alzheimers Dis"},{"key":"586_CR124","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/2051-5960-1-28","volume":"1","author":"AA Motsinger-Reif","year":"2013","unstructured":"Motsinger-Reif AA, Zhu H, Kling MA, Matson W, Sharma S, Fiehn O, et al. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer\u2019s disease from normal cognitive aging. Acta Neuropathol Commun. 2013;1:28.","journal-title":"Acta Neuropathol Commun."},{"issue":"4","key":"586_CR125","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nm.3466","volume":"20","author":"M Mapstone","year":"2014","unstructured":"Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014;20(4):415\u20138.","journal-title":"Nat Med"},{"issue":"7","key":"586_CR126","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jalz.2015.12.008","volume":"12","author":"R Casanova","year":"2016","unstructured":"Casanova R, Varma S, Simpson B, Kim M, An Y, Saldana S, et al. Blood metabolite markers of preclinical Alzheimer\u2019s disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement. 2016;12(7):815\u201322.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"586_CR127","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jalz.2017.01.020","volume":"13","author":"JB Toledo","year":"2017","unstructured":"Toledo JB, Arnold M, Kastenmuller G, Chang R, Baillie RA, Han X, et al. Metabolic network failures in Alzheimer\u2019s disease: a biochemical road map. Alzheimers Dement. 2017;13(9):965\u201384.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"586_CR128","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.jalz.2019.03.004","volume":"15","author":"M Kim","year":"2019","unstructured":"Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, et al. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European medical information framework for Alzheimer\u2019s disease biomarker discovery cohort. Alzheimers Dement. 2019;15(6):817\u201327.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"586_CR129","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jalz.2018.08.012","volume":"15","author":"K Nho","year":"2019","unstructured":"Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, et al. Altered bile acid profile in mild cognitive impairment and Alzheimer\u2019s disease: relationship to neuroimaging and CSF biomarkers. Alzheimers Dement. 2019;15(2):232\u201344.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-020-00586-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:10:45Z","timestamp":1614384645000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00586-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00586-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,28]]},"assertion":[{"value":"8 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Biogen and Alzecure and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (all outside submitted work). The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}